The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.
Julian Molina, MD, PhD
Advertisement
Hematologist/oncologist at Mayo Clinic
Articles by Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.
The hematologist/oncologist from Mayo Clinic discussed the growing presence of CAR T-cell therapies in lung cancer and melanoma.
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.
The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in a variety of cancers.
Advertisement
Latest Updated Articles
Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhDPublished: January 17th 2022 | Updated:
- Improving Cancer Survival With Immunotherapy: Julian Molina, MD, PhD
Published: January 8th 2022 | Updated:
- Using HLA LOH as a Biomarker in Targeting Cancers: Julian Molina, MD, PhD
Published: December 9th 2021 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – November 26, 2025
2
FDA Approves Itvisma, a New Intrathecal Route for Novartis’ SMA Gene Therapy
3
Guess the Therapy Answer November 26, 2025
4
Sarepta's Elevidys Gets Boxed Warning for ALI and ALF
5
